The Japanese Ministry of Health, Labour and Welfare has approved zolbetuximab for CLDN18.2-positive, unresectable, advanced or recurrent gastric cancer.
/PRNewswire/ The medical device industry is constantly evolving, and the adoption of new technologies is driving growth and innovation. The top 10 medical.